Graham Capital Management L.P. Increases Holdings in Natera, Inc. $NTRA

Graham Capital Management L.P. lifted its position in shares of Natera, Inc. (NASDAQ:NTRA) by 729.7% during the 4th quarter, Holdings Channel.com reports. The fund owned 25,747 shares of the medical research company’s stock after buying an additional 22,644 shares during the period. Graham Capital Management L.P.’s holdings in Natera were worth $5,898,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Persistent Asset Partners Ltd purchased a new stake in shares of Natera during the 4th quarter worth approximately $340,000. Polar Capital Holdings Plc purchased a new stake in shares of Natera during the 4th quarter worth approximately $1,913,000. Rothschild Wealth LLC purchased a new stake in shares of Natera during the 4th quarter worth approximately $412,000. Aster Capital Management DIFC Ltd purchased a new stake in shares of Natera during the 4th quarter worth approximately $131,000. Finally, Board of Trustees of The Leland Stanford Junior University purchased a new stake in shares of Natera during the 4th quarter worth approximately $7,171,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Insider Transactions at Natera

In related news, Director Roelof Botha sold 78,000 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $220.31, for a total value of $17,184,180.00. Following the completion of the transaction, the director owned 1,076,198 shares of the company’s stock, valued at approximately $237,097,181.38. The trade was a 6.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Gail Boxer Marcus sold 11,000 shares of the business’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $217.21, for a total transaction of $2,389,310.00. Following the completion of the transaction, the director directly owned 6,183 shares of the company’s stock, valued at $1,343,009.43. The trade was a 64.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 159,378 shares of company stock worth $34,640,860 in the last ninety days. Company insiders own 5.05% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. William Blair assumed coverage on Natera in a research note on Tuesday, April 14th. They set an “outperform” rating on the stock. Royal Bank Of Canada assumed coverage on Natera in a research note on Thursday, June 11th. They set an “outperform” rating and a $275.00 price target on the stock. Wolfe Research assumed coverage on Natera in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 price target on the stock. Robert W. Baird set a $265.00 price target on Natera in a research note on Friday, May 8th. Finally, Evercore reissued an “outperform” rating and set a $270.00 price target on shares of Natera in a research note on Friday, May 8th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $256.53.

Natera Trading Up 1.4%

Natera stock opened at $220.11 on Wednesday. The stock has a market cap of $31.52 billion, a PE ratio of -135.04 and a beta of 1.56. The stock has a 50-day moving average price of $206.92 and a 200 day moving average price of $215.57. Natera, Inc. has a 52 week low of $131.81 and a 52 week high of $256.36.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.